TW443935B - Method for preparing microfluidized particles of atovaquone, and pharmaceutical compositions comprising microfluidized particles of atovaquone - Google Patents
Method for preparing microfluidized particles of atovaquone, and pharmaceutical compositions comprising microfluidized particles of atovaquone Download PDFInfo
- Publication number
- TW443935B TW443935B TW082110927A TW82110927A TW443935B TW 443935 B TW443935 B TW 443935B TW 082110927 A TW082110927 A TW 082110927A TW 82110927 A TW82110927 A TW 82110927A TW 443935 B TW443935 B TW 443935B
- Authority
- TW
- Taiwan
- Prior art keywords
- atovikon
- particles
- patent application
- mixture
- microfluidized
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 25
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 title claims abstract description 11
- 229960003159 atovaquone Drugs 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000375 suspending agent Substances 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 230000002079 cooperative effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 241000224483 Coccidia Species 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 2
- 241000597310 Imeria <wasp> Species 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 238000007639 printing Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000414668 Tabanus par Species 0.000 description 1
- 241000223777 Theileria Species 0.000 description 1
- 241001586444 Trilophidia annulata Species 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000009957 hemming Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fertilizers (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medicines Containing Plant Substances (AREA)
Description
139 3 5 苐 »2 L iUy27 中衮說明晝絛里夏 民國88年2月修正 阿托維康 五、發明説明(1 ) 本發明是有關於2 —〔4 — (4 一氯苯基)環己基〕 一 3 —羥基一 1 ,4-某醌的微流體化粒子,以及有關其 製備方法。本發明尤其是有關於含有2 —〔4- (4 —氯 苯基)環己基〕—3 -羥基一 1,4 —棻醌 ’ 1 atovaquone)的微流體化粒子藥用組成物,及其在治 療上的用途β 之前已有人對阿托維康加以說明,比如參見歐洲專利 號碼0123238和美國專利號碼5053432(在 此納入參考文獻),是有關於化學式(I)的2-取代一 3 -羥基_1,4 —某醌: (请先閲讀背面之注意事項再填寫本頁)
(I) 經濟部中央橾準局貝Μ消費合作社印裝 os i s )的病媒,而 其中R1爲氫,R2選自烷氧基、芳烷氧基、烷 基一Cpe烷氧基、由一個或兩個選自鹵素和Ci_6烷基、 鹵素和髙鹵素一 Ci-e烷基或取代的苯基,R1和R2二者 爲烷基或苯基,且η爲0或1,及其生理上可接受 的鹽類。該化合物據說有抵抗原生動物的活性。明確的講 ,η爲0之化學式(I )的化合物據說具有抵抗人體瘧疾 寄生 Plasmodinm falcinarum^ 活性,並可抵抗像 E. tene-1 1 a 和 R. acervnl ina 的 E i m e r i a 種一這是球蟲症(coccidi- 之分子式(I )的化合物據說具 本纸張尺度適用1P國國家標準(CNS ) A4規格(210 X 297公釐) -3 ~ 4439 3 5 A6 B6 五、發明説明(2 ) 有抗泰蟲(Theileria)厲,尤其是T.annulate或T. pa r va ,原生動物的活性。在明確指明和所舉例的化合物 ,爲n = 0 'R1爲氫且R2爲4 —氯苯基的化_式(I ) 化合物,比如阿托維康。 EP 0362996說明阿托維康在治療和/或預 防肺囊種cariuii菌肺炎的用途。 阿托維康對毒漿體原蟲病弓蟲症(Τ〇χ〇ρ丨asmosis)和 隱胞子蟲症(Cryptosporidiosis)的另外用途分別在欧洲 專利公布號碼0 4 4 5 1 4 1和0 4 9 6 7 2 9中有所說 明。 阿托維康作治療劑的功效會受其生物可應用性限制。 因此本發明的目的在提供有較多生物可應用形式的阿托維 康。 如今吾人發現只要確保粒子大小爲在某預定範圍內的 小粒子即可增加阿托維康的生物可應用性。然而,吾人亦 發現,使用減少阿托維康粒子大小的傳統方法來產製帶有 改良之生物可應用性所需大小的粒子並未成功。 微流化器爲Microfluidics公司自1 9 8 5年開始行 銷。其操作原則是根據浸入噴射技術。它主要被設計在食 品和製薬工業上用作均一化裝置以製備像乳液和脂質體( lipsomal)系統,稍後被使用在生物科技應用上作細胞一 破裂用。 吾人很訝異的發現利用微流化器所製成的呵托維康微 流體化粒子具有化合物之改良式生物可應用性。吾人確信 ί請先閲讀背面之注意事項再填寫本頁) 本纸張疋度遇用_ a 3家樣準;CNS! »4规格1210X297公;® 4439 3 5 Α6 Β6 五、發明説明(3 ) 這是因爲微流體化阿托維康粒子的較小尺寸和窄的粒子範 圃以致。 在操作微流化器時,以馬達將氣流供應至特殊設計的 器室中,在此流體氣流會以非常髙的速度和壓力來作用。 在作用室中的固定微通道可提供密集渦流的特別集中反應 带,而可在空洞和剪力間引起能量的釋出。在不拘泥於理 論下,吾人確信由於所有產物通過大小固定的能置釋出區 域,使用微流體器會較傅統製造微細粒子的方法可達到較 大的粒子均一性和較小的尺寸。 於是第一,本發明可提供阿托維康的小粒子。粒子較 宜爲微流體化粒子。適宜至少9 0 %粒子的容稹直徑在 0 . 1 — 3微米間。較宜至少9 5%粒子的容稹直徑在 0 . 1 — 2微米間。 第二,本發明提供含有阿托維康粒子和一個或以上其 可供製藥載體的藥用組成物,其中至少9 5 %粒子的容積 直徑在0 .1_2微米間。粒子較宜爲微流體化粒子。 載體必須是組成物中其他成份在相容性上可接受的, 並且不會對其受體有害處。 第三點,本發明提供製備阿托維康微流體化粒子的方 法,它包括使阿托維康和液體賦形劑(vehicle)混合來 提供其中阿托維康的濃度少於4 5 Omg/mL的混合物 ,並使該混合物通過微流化器3次以提供粒子形式爲至少 9 0 %粒子的容稹直徑在0 . 1 — 3微米間的阿托維康。 較宜爲至少95%粒子的容稹直徑在0 .1—2微米間。 (請先闖讀背面之注意事項再填窍衣頁) 本纸法又度適用办I J家標準.:CN’S,®4規格__210X297公坌| 4439 3 5 A6 B6 經濟部中夬桴羋局Μ工消贵合泎杜印% 五、發明説明ί4 ) 最後一點,本發明可提供一種製備藥用組成物的方法 ,它包括以下歩驟: a) 使阿托維康和液體賦形劑混合來提供阿托維康濃 度少於4 5 Omg/mL的混合物。 b) 使該混合物通過微流化器3次以提供粒子形式爲 至少9 0 %粒子的容稹直徑在0 . 1_3微米間的阿托維 康。 c) 使微流體化製備物和一個或以上其藥用可接受載 體混合。 適宜使混合物通過微體器1 0 — 5 0次,比如通過 2 5 - 3 0次。較宜使混合物通過微流饅器1 5_2 5次 0 在一個體系中,液體賦彤劑爲表面活性劑。液體賦形 劑較宜爲表面活性劑溶液。在一個特別逋宜的體系中,表 面活性劑爲PoUxamer 188溶液。在另外一個較適宜體系 中,薬用可接受載體包括懸浮劑。適用的懸浮劑包括甲基 織維素和黃原(xan than)膠。懸浮劑較宜爲黃原膠。 藥用組成物包括口服劑和針劑(包含皮下·、眞皮、肌 肉和靜脈注射),以及鼻(iiaso)-胃管。在本發明範園 內適用的組成物包括,舉例來說,像錠片的固體劑量形式 和像懸浮液-較適宜的組成物-的液體劑量彤式。組成物 可在適合處方便以個別劑量單位存在,並可以製藥技術已 知的方法來由微流體化粒子製備。 量測阿托維康在活髗(vivo)上生物可應用性的試驗 本纸張尺度命占a家標準^CNS;甲4規格(210x297公芨i 6 - ...................................................................................^......................1Τ................... 4 (請先閉讀背面之注意事項再崤寫本頁) 4439 3 5 A6 _B6_ 五、發明説明(5 ) 指出,和先前技術的組成物相較,微流體化阿托維康組成 物有改良之生物可應用性。因此本發明進一步提供具有治 療用途的微流體化阿托維康組成物,尤其是在原生動物寄 生感染一比如癍疾和住血原蟲症一以及受P. car inii感染 等的治療和預防。 窗施例1 阿托維庚微流體化粒子的製備 阿托維康是以先前技術,比如美國專利號碼 5 0 5 3 4 3 2 (在此納入參考文獻),來製備。製備 6 0 0毫升含有2 . 5%w/v阿托維康的〇 · 2 5% w / v Celacol M2 5 0 0混合物,保留1 0 0毫升於 玻璃廣口瓶中作控制組。使實驗室級1 2 Ο B型微流化器 和9 0 psi壓縮空氣供應源相接,並調整生成的流體壓力 爲1 5 0 0 0 p s i 。將機器底座、微流化器的作用室和 管線浸入冷水浴中。將5 Q 0毫升的混合物加入微流化器 的大瓶中,並在回流到巨室的頂端和側面前先通過微流體 器的作用室中。混合物持績流過反應室,並在1 〇、2 0 、3 〇、4 5和6 0分鏟時取樣。計算各個樣品的流通數 ...........」-….................. .......................:裝.....................訂..................4 (請先閱讀背面之注意事項再填寫本頁一 經濟邾办央標准局S-X-消赍合作社印装 中 1 表 付 的 面 下 在 列 並 本紙法尺戊通用令曳邊家標举|:CN'sif4規格|:210x297公爱1 4439 3 5 B6 五、發明說明(6 ) 附表1 S-m. 邀流麝化眭閱 (分鐘) 稂 容 a #1 數 次 通 流 升 毫 控制組 1 2 3 4 5
ο ο IX 5 ο
5 ο X ο 1 1 5 5 ο 3 1 9 5 6 8 9 ΊΧ 5 3 7 7 4 4 2 I 2 4 1± 以4 0 X放大倍率顯微鏡來觀察控制組和樣品,結果 如下: 控制組—不同的形狀,平板,棒狀和sher01d,通常爲 5X5微米,最大爲7 _ 5X1 〇微米,鬆散聚 集。 樣品1 一較成®形的較小形狀,有些、大塊,晶體,許多 2·5X2.5微米的小碎片,較分散。 樣品2 -較成圓形,較小的形狀,較多的碎片。 樣品3 —仍然較成圓形,較小的形狀,較多的碎片。 樣品4 -仍然較成圓形,較小的形狀,較多的碎片。 樣品5-非常小的粒子,全部在2.5微米以下,全部成 f請先閱讀背面之注意事項再填寫本頁〕 -裝 訂 本纸淺尺度適用中3圉家標4MCNS!甲4規格!210X 297公凳1 4439 3 5 五、發明説明7 ) 圓形,成單分散。 窗施例2 混合下列的成份來製備口服懸浮液成份物: A6 B6 阿托維康的微流體化粒子 15 0 .0奄克 Poloxamer 188 5 .0毫克 苯甲醇 1 0 .0毫克 黃原膠 7 .5奄克 純水 需製造 1 .0毫升 啻施例3 在一個隨機交叉硏究中,九名健康、斷食男性自願者 接受單一劑量爲5mg/mL的懸浮液,其中含有2 5 〇 毫克、平均大小爲3微米的阿托維康懸浮液和1撖米微流 儺化懸浮液。在最後一劑服完後,間隔最多兩週抽取血纸 樣品,並以HPLC分析。結果列在下面的附表2。 装...................t ..............!:.φτ (請先聞讀背面之注意事項再塡寫各頁】 *1齊部t夬sis局:"工消迕合"社印% 本紙張尺度逍用中U家標準i.C.VS)甲4规格1.210X 297公釐) 4439 3 f A6 B6 五、發明説明(8 ) 附表2 3微米懸浮液 1微米懸浮液 平均(SD)AUC 95(62) u g/raL . h 247(85) μ g/mL . h 平均(SD)Cmax 1 . 2 ( Ο . 7 ) /i g/iL 5.0(1.6)// g/nL 中間Tmu 5小時 1小時 (請先閱讀背面之注意事項再填寫本頁) 微米懸浮液的AU C相對於3微米懸浮液的平均 %CI)遞增爲2.6倍( 3
而C 裝 則爲4 . 1倍 .5 — 訂 蛵濟邾中夬桴;tts)H工消赍合::?社印製 準 標 家 a f 用 ;4 尺 長 本 規 - 7 -9 ο Ti
Claims (1)
- “39 3 5 A8 B8 C8 D8 經濟邹智慧財產局員Η消費合作社印製 申請專利範圍 附件一(A 第82 1 1 0 927號專利申請案 中文申請專利範圍修正本 民國9 0年3月呈 1·一種製備阿托維康微流體化粒子的方法,包括使 阿托維康和液體賦形劑混合以提供一種其中阿托維康濃度 低於4 5 Omg/mL的混合物,稍後使該混合物通過微 流化器至少三次,以使阿托維康粒子得以微流體化。 2 . —種製備呈懸浮液形式之醫藥組成物的方法,該 方法包括以下步驟: a)使阿托維康和液體賦形劑混合來提供阿托維康濃 度少於4 5 Omg/mL的混合物, b )使該混合物通過微流化器至少3 .次以提供微流體 化製劑,其中阿托維康係呈粒子形式,而且有至少9 ◦ % 之粒子其容積直徑在〇1一3微米間, c)使微流體化製劑和一種或一種以上之藥用可接受 載體混合。 3·如申請專利範圍第1或2項的方法,其中使該混 合物通過微流化器1 0至5 0次。 4 .如申請專利範圍第3項的方法,其中使該混合物 通過微流化器15 — 2 5次》 5 _如申請專利範圍第2項的方法,其中該液體賦形 劑爲表面活性劑溶液。 私紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --^.!-------- ^-------- 訂·!-------^ (請先閲讀背面之注意事項再填窝本頁) 44393F A8 B8 C8 D8 夂、申請專利範圍 6.如申請專利範圍第5項的方法’其中該表面活性 劑溶液爲Poloxamer 188溶液。 7 .如申請專利範圍第5項的方法,其中該藥用可接 受載體包括懸浮劑。 8 _如申請專利範圍第7項的方法,其中該懸浮劑爲 黃原膠。 9 . 一種用於治療感染之醫藥組成物,係由 Η π If專利 範圍第2至8項中任一項之方法所製成的。 (琦先閱讀背面之注意事項再填寫本頁) --------訂----- ^ 經濟部智慧財產局員工消費合作杜印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐 附件:第82110927號專利申請案中文說明書修正頁— 民固邱年11月呈 申請曰期 82年12月 23日 案 號 82110927 1 類 別 AilK ViL \ (以上各襴由本局填註) 」Α4 C4 443935 霧|專利説明書 中文 發明 新型 名稱 英 文 Method for preparing vicrofluidised perticles of atovaquone, and phaxaaceutical compositions co_prising juinrnf tinHi cori part iotas nf fttovnqnnnB_ 姓 名 國 藉 發明 創作/ ⑴艾徐•迪思Dearn, Alan Roy(1)英囲 (1)英团肯特D A 1 5 A H ·達待福•聖殿丘 Teaple HilU Dartford, Kent DAI 5ΑΗ» England 裝 住、居所 訂 姓 名 (名稱) (1)威莆康基金股份有限公司 The Vellcoae Foundation Li>ited 經濟部中央標準局負工消費合作社印装 線 三、申請人 國 籍 住、居所 (事務所) 代表人 姓 名 α)英囲⑴英团米德Μ斯格林福伯克萊大道格雷斯大裹 Glaxo Vellcoae House* Berkeley Avenue, Greenford, Middlesex UB6 0NNt United Kingdoa ⑴赛門•畢克尼爾Bicknell, SUon 本紙張尺度逋用中國國家樣率(CNS ) A4規格(2!0X297公釐) 139 3 5 苐 »2 L iUy27 中衮說明晝絛里夏 民國88年2月修正 阿托維康 五、發明説明(1 ) 本發明是有關於2 —〔4 — (4 一氯苯基)環己基〕 一 3 —羥基一 1 ,4-某醌的微流體化粒子,以及有關其 製備方法。本發明尤其是有關於含有2 —〔4- (4 —氯 苯基)環己基〕—3 -羥基一 1,4 —棻醌 ’ 1 atovaquone)的微流體化粒子藥用組成物,及其在治 療上的用途β 之前已有人對阿托維康加以說明,比如參見歐洲專利 號碼0123238和美國專利號碼5053432(在 此納入參考文獻),是有關於化學式(I)的2-取代一 3 -羥基_1,4 —某醌: (请先閲讀背面之注意事項再填寫本頁)(I) 經濟部中央橾準局貝Μ消費合作社印裝 os i s )的病媒,而 其中R1爲氫,R2選自烷氧基、芳烷氧基、烷 基一Cpe烷氧基、由一個或兩個選自鹵素和Ci_6烷基、 鹵素和髙鹵素一 Ci-e烷基或取代的苯基,R1和R2二者 爲烷基或苯基,且η爲0或1,及其生理上可接受 的鹽類。該化合物據說有抵抗原生動物的活性。明確的講 ,η爲0之化學式(I )的化合物據說具有抵抗人體瘧疾 寄生 Plasmodinm falcinarum^ 活性,並可抵抗像 E. tene-1 1 a 和 R. acervnl ina 的 E i m e r i a 種一這是球蟲症(coccidi- 之分子式(I )的化合物據說具 本纸張尺度適用1P國國家標準(CNS ) A4規格(210 X 297公釐) -3 ~ 3 9 3 4 4 广% 正充 修補 5 B 明 發 /f\ 要 摘 明 發 文 中 四 稱 .法醫 方之 備子 製粒 之康 子維 粒托 康阿 維化 托體 阿流 化微物 體有成 流含組 微及藥 ,帶 子於 粒關 化有 體是 流明 微發 的本 康, 維是 托的 阿別 於特 關較 有。 是法 明方 發備 本製 其 於 物 成 組 用 藥 的 子 粒 化 體 流 微 的 康 • _lc 維。 托用 阿使 性的 用上 可療 物治 生在 關之其 有良 及改 以有 及 (請先聞讀背面之注意事項再填寫本頁各攔) 經濟部中央標準局負工消費合作社印裝 英文發明摘要(發明之名稱: ABSTRACT METHOD FOR PREPARING MICROFLUIDIZED PARTICLES OF ATOVAQUONE, AND PHARMACEUTICAL COMPOSITIONS COMPRISING MICR0FLUIDI-ZED PARTICLES OF ATOVAQUONE The invention relates to microfluidised particles of atovaquone and to a method of preparing them. More particularly, the invention is concerned with a pharmaceutical composition containing microfluidised particles of atovaquone which has improved bioavailability and its use in therapy. 本紙張尺度適用中國國家榡準(CNS ) A4規格(210X297公嫠) “39 3 5 A8 B8 C8 D8 經濟邹智慧財產局員Η消費合作社印製 申請專利範圍 附件一(A 第82 1 1 0 927號專利申請案 中文申請專利範圍修正本 民國9 0年3月呈 1·一種製備阿托維康微流體化粒子的方法,包括使 阿托維康和液體賦形劑混合以提供一種其中阿托維康濃度 低於4 5 Omg/mL的混合物,稍後使該混合物通過微 流化器至少三次,以使阿托維康粒子得以微流體化。 2 . —種製備呈懸浮液形式之醫藥組成物的方法,該 方法包括以下步驟: a)使阿托維康和液體賦形劑混合來提供阿托維康濃 度少於4 5 Omg/mL的混合物, b )使該混合物通過微流化器至少3 .次以提供微流體 化製劑,其中阿托維康係呈粒子形式,而且有至少9 ◦ % 之粒子其容積直徑在〇1一3微米間, c)使微流體化製劑和一種或一種以上之藥用可接受 載體混合。 3·如申請專利範圍第1或2項的方法,其中使該混 合物通過微流化器1 0至5 0次。 4 .如申請專利範圍第3項的方法,其中使該混合物 通過微流化器15 — 2 5次》 5 _如申請專利範圍第2項的方法,其中該液體賦形 劑爲表面活性劑溶液。 私紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --^.!-------- ^-------- 訂·!-------^ (請先閲讀背面之注意事項再填窝本頁)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929226905A GB9226905D0 (en) | 1992-12-24 | 1992-12-24 | Pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
TW443935B true TW443935B (en) | 2001-07-01 |
Family
ID=10727175
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088101847A TW514531B (en) | 1992-12-24 | 1993-12-23 | Method for preparing microfluidised particles of atovaquone, and pharmaceutical compositions comprising microfluidized particles of atovaquone |
TW082110927A TW443935B (en) | 1992-12-24 | 1993-12-23 | Method for preparing microfluidized particles of atovaquone, and pharmaceutical compositions comprising microfluidized particles of atovaquone |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088101847A TW514531B (en) | 1992-12-24 | 1993-12-23 | Method for preparing microfluidised particles of atovaquone, and pharmaceutical compositions comprising microfluidized particles of atovaquone |
Country Status (36)
Country | Link |
---|---|
US (2) | US6018080A (zh) |
EP (1) | EP0675711B1 (zh) |
JP (1) | JP3461353B2 (zh) |
KR (1) | KR0175193B1 (zh) |
CN (1) | CN1076194C (zh) |
AT (1) | ATE169215T1 (zh) |
AU (2) | AU675102B2 (zh) |
BG (1) | BG61932B1 (zh) |
BR (1) | BR9307719A (zh) |
CA (1) | CA2152615C (zh) |
CZ (1) | CZ289701B6 (zh) |
DE (1) | DE69320208T2 (zh) |
DK (1) | DK0675711T3 (zh) |
ES (1) | ES2122223T3 (zh) |
FI (1) | FI114007B (zh) |
GB (1) | GB9226905D0 (zh) |
GE (1) | GEP19991515B (zh) |
HK (1) | HK1004086A1 (zh) |
HR (1) | HRP931516B1 (zh) |
HU (1) | HU220215B (zh) |
IL (1) | IL108154A (zh) |
MY (1) | MY109990A (zh) |
NO (1) | NO316745B1 (zh) |
NZ (1) | NZ258995A (zh) |
PL (1) | PL175374B1 (zh) |
RO (1) | RO119686B1 (zh) |
RU (1) | RU2127585C1 (zh) |
SA (1) | SA94140644B1 (zh) |
SG (1) | SG43901A1 (zh) |
SI (1) | SI9300678A (zh) |
SK (1) | SK281924B6 (zh) |
TW (2) | TW514531B (zh) |
UA (1) | UA39879C2 (zh) |
WO (1) | WO1994014426A1 (zh) |
YU (1) | YU48919B (zh) |
ZA (1) | ZA939673B (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224739D0 (en) * | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
AU3705695A (en) * | 1994-10-26 | 1996-05-23 | Wellcome Foundation Limited, The | Pharmaceutical composition comprising atovaquone |
DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
GB9424013D0 (en) * | 1994-11-29 | 1995-01-18 | Wellcome Found | Medicaments |
AU753278B2 (en) * | 1998-02-25 | 2002-10-10 | Abbott Laboratories | Butorphanol sustained release formulations |
US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6706744B2 (en) | 2000-11-17 | 2004-03-16 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
AU2002223500A1 (en) | 2000-11-17 | 2002-05-27 | Novo-Nordisk A/S | Glucagon antagonists/inverse agonists |
US6821960B2 (en) | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
US7183518B2 (en) * | 2004-09-24 | 2007-02-27 | Michael Near | System of food storage preparation and delivery in finished cooked state |
DE102005011786A1 (de) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
JP5080445B2 (ja) * | 2005-04-13 | 2012-11-21 | アボット ゲーエムベーハー ウント コー. カーゲー | 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用 |
US20080241254A1 (en) * | 2007-01-02 | 2008-10-02 | Suryakant Navale | Pharmaceutical composition comprising atovaquone particles |
DE102007001473A1 (de) | 2007-01-08 | 2008-07-10 | Andreas Lemke | Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck |
WO2009007991A2 (en) * | 2007-04-19 | 2009-01-15 | Ipca Laboratories Limited | A new process for preparation of atovaquone and novel intermediates thereof |
US20110206770A1 (en) * | 2008-07-25 | 2011-08-25 | Alphapharm Pty. Ltd. | Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns |
US20100099776A1 (en) * | 2008-10-20 | 2010-04-22 | Ranbaxy Laboratories Limited | Oily suspension of atovaquone |
WO2011021230A2 (en) | 2009-08-20 | 2011-02-24 | Ipca Laboratories Limited | Novel complex for treatment and/or prophylaxis of parasitic infections |
MX337893B (es) * | 2009-11-10 | 2016-03-28 | Celgene Corp | Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. |
WO2011151418A2 (en) | 2010-06-02 | 2011-12-08 | Abbott Gmbh & Co. Kg | Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase |
EP2934484A1 (en) | 2012-12-19 | 2015-10-28 | Kashiv Pharma, LLC | Supersaturated stabilized nanoparticles for poorly soluble drugs |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
EP3471697A1 (en) * | 2016-06-16 | 2019-04-24 | The University of Liverpool | Chemical composition |
US20220265566A1 (en) * | 2018-10-18 | 2022-08-25 | Tulex Pharmaceuticals Inc. | Atovaquone nanoparticulate compositions |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2533648A (en) * | 1949-03-05 | 1950-12-12 | Joseph H Warburg | Circular saw making |
NL6411993A (zh) * | 1963-10-18 | 1965-04-20 | ||
US3347830A (en) * | 1964-07-30 | 1967-10-17 | Grace W R & Co | Process of polymerizing formaldehyde |
GB1141735A (en) * | 1966-11-23 | 1969-01-29 | Pfizer & Co C | Pharmaceutical anti-tumor composition |
US3655699A (en) * | 1970-03-02 | 1972-04-11 | Pfizer | Analogues of lapachol as antitumor agents |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
DE2601458A1 (de) * | 1975-01-20 | 1976-07-22 | Ciba Geigy Ag | Loesliche, von phenylindandiaminen abgeleitete polyamide |
EG14152A (en) * | 1977-11-22 | 1983-12-31 | Wellcome Found | Antitheilerial naphtoquinone derivatives |
US4485117A (en) | 1981-10-16 | 1984-11-27 | Hudson Alan T | Antiprotozoal compounds |
US4485116A (en) * | 1981-10-16 | 1984-11-27 | Hudson Alan T | Antiprotozoal compounds |
DE3141691A1 (de) * | 1981-10-21 | 1983-05-19 | Hoechst Ag, 6230 Frankfurt | Plasmid pac 1, verfahren zu seiner gewinnung und seine verwendung |
US5053432A (en) * | 1983-04-14 | 1991-10-01 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
GB8310141D0 (en) * | 1983-04-14 | 1983-05-18 | Wellcome Found | Naphthoquinone derivatives |
US5175319A (en) | 1983-04-14 | 1992-12-29 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
GB8310140D0 (en) * | 1983-04-14 | 1983-05-18 | Wellcome Found | Antiprotozoal agents |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
PL276385A1 (en) * | 1987-01-30 | 1989-07-24 | Exxon Chemical Patents Inc | Method for polymerization of olefines,diolefins and acetylene unsaturated compounds |
IL85097A (en) * | 1987-01-30 | 1992-02-16 | Exxon Chemical Patents Inc | Catalysts based on derivatives of a bis(cyclopentadienyl)group ivb metal compound,their preparation and their use in polymerization processes |
US4783389A (en) * | 1987-03-27 | 1988-11-08 | E. I. Du Pont De Nemours And Company | Process for preparation of liquid electrostatic developers |
US5155080A (en) * | 1988-07-15 | 1992-10-13 | Fina Technology, Inc. | Process and catalyst for producing syndiotactic polyolefins |
US5225500A (en) * | 1988-07-15 | 1993-07-06 | Fina Technology, Inc. | Process and catalyst for producing syndiotactic polyolefins |
GB8819477D0 (en) * | 1988-08-16 | 1988-09-21 | Wellcome Found | Medicaments |
US5206268A (en) * | 1988-08-16 | 1993-04-27 | Burroughs Wellcome Co. | Medicaments |
US5225184A (en) * | 1988-08-16 | 1993-07-06 | Burroughs Wellcome Co. | Medicaments |
DE68928964T2 (de) * | 1988-08-16 | 1999-07-29 | Wellcome Found | Neue Naphthochinone und ihre Anwendung als Arzneimittel |
KR930002411B1 (ko) * | 1988-09-14 | 1993-03-30 | 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 | 벤젠불용성 유기알루미늄 옥시화합물 및 그 제조방법 |
GB8921516D0 (en) * | 1989-09-22 | 1989-11-08 | Wellcome Found | Medicaments |
CA2027145C (en) * | 1989-10-10 | 2002-12-10 | Michael J. Elder | Metallocene catalysts with lewis acids and aluminum alkyls |
GB8923254D0 (en) * | 1989-10-16 | 1989-12-06 | Wellcome Found | Medicaments |
CA2027122C (en) * | 1989-10-30 | 2002-12-10 | John A. Ewen | Making metallocene catalysts using aluminum alkyls for controlled polymerization of olefins |
US5387568A (en) * | 1989-10-30 | 1995-02-07 | Fina Technology, Inc. | Preparation of metallocene catalysts for polymerization of olefins |
DE3942363A1 (de) * | 1989-12-21 | 1991-06-27 | Hoechst Ag | Verfahren zur herstellung einer polypropylen-formmasse |
JP2545006B2 (ja) * | 1990-07-03 | 1996-10-16 | ザ ダウ ケミカル カンパニー | 付加重合触媒 |
JP3076619B2 (ja) | 1991-05-14 | 2000-08-14 | 三井化学株式会社 | ブロック共重合体の製造方法 |
GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5766522A (en) * | 1996-07-19 | 1998-06-16 | Morton International, Inc. | Continuous processing of powder coating compositions |
US5976578A (en) * | 1996-10-10 | 1999-11-02 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
US5914135A (en) * | 1997-04-16 | 1999-06-22 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
-
1992
- 1992-12-24 GB GB929226905A patent/GB9226905D0/en active Pending
-
1993
- 1993-12-20 GE GEAP19931692A patent/GEP19991515B/en unknown
- 1993-12-22 YU YU80893A patent/YU48919B/sh unknown
- 1993-12-23 JP JP51496894A patent/JP3461353B2/ja not_active Expired - Lifetime
- 1993-12-23 ZA ZA939673A patent/ZA939673B/xx unknown
- 1993-12-23 DK DK94902952T patent/DK0675711T3/da active
- 1993-12-23 RU RU95122758A patent/RU2127585C1/ru active
- 1993-12-23 TW TW088101847A patent/TW514531B/zh not_active IP Right Cessation
- 1993-12-23 SI SI9300678A patent/SI9300678A/sl unknown
- 1993-12-23 EP EP94902952A patent/EP0675711B1/en not_active Expired - Lifetime
- 1993-12-23 CA CA002152615A patent/CA2152615C/en not_active Expired - Lifetime
- 1993-12-23 UA UA95062971A patent/UA39879C2/uk unknown
- 1993-12-23 PL PL93309629A patent/PL175374B1/pl unknown
- 1993-12-23 HU HU9501812A patent/HU220215B/hu unknown
- 1993-12-23 AT AT94902952T patent/ATE169215T1/de active
- 1993-12-23 RO RO95-01191A patent/RO119686B1/ro unknown
- 1993-12-23 MY MYPI93002823A patent/MY109990A/en unknown
- 1993-12-23 BR BR9307719-0A patent/BR9307719A/pt not_active Application Discontinuation
- 1993-12-23 AU AU57105/94A patent/AU675102B2/en not_active Expired
- 1993-12-23 DE DE69320208T patent/DE69320208T2/de not_active Expired - Lifetime
- 1993-12-23 WO PCT/GB1993/002646 patent/WO1994014426A1/en active IP Right Grant
- 1993-12-23 SK SK828-95A patent/SK281924B6/sk not_active IP Right Cessation
- 1993-12-23 NZ NZ258995A patent/NZ258995A/en not_active IP Right Cessation
- 1993-12-23 CN CN93121376A patent/CN1076194C/zh not_active Expired - Fee Related
- 1993-12-23 SG SG1996004546A patent/SG43901A1/en unknown
- 1993-12-23 HR HR9226905.9A patent/HRP931516B1/xx not_active IP Right Cessation
- 1993-12-23 TW TW082110927A patent/TW443935B/zh not_active IP Right Cessation
- 1993-12-23 ES ES94902952T patent/ES2122223T3/es not_active Expired - Lifetime
- 1993-12-23 CZ CZ19951451A patent/CZ289701B6/cs not_active IP Right Cessation
- 1993-12-23 KR KR1019950702217A patent/KR0175193B1/ko not_active IP Right Cessation
- 1993-12-23 IL IL10815493A patent/IL108154A/xx not_active IP Right Cessation
-
1994
- 1994-04-03 SA SA94140644A patent/SA94140644B1/ar unknown
-
1995
- 1995-06-15 BG BG99723A patent/BG61932B1/bg unknown
- 1995-06-22 FI FI953139A patent/FI114007B/fi not_active IP Right Cessation
- 1995-06-22 NO NO19952522A patent/NO316745B1/no not_active IP Right Cessation
-
1997
- 1997-03-14 AU AU16279/97A patent/AU696662B2/en not_active Ceased
- 1997-11-19 US US08/974,248 patent/US6018080A/en not_active Expired - Lifetime
-
1998
- 1998-04-20 HK HK98103299A patent/HK1004086A1/xx not_active IP Right Cessation
-
1999
- 1999-10-04 US US09/411,381 patent/US6649659B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW443935B (en) | Method for preparing microfluidized particles of atovaquone, and pharmaceutical compositions comprising microfluidized particles of atovaquone | |
Dauty et al. | Dimerizable cationic detergents with a low cmc condense plasmid DNA into nanometric particles and transfect cells in culture | |
Cartwright et al. | Chemical, clinical, and immunological studies on the products of human plasma fractionation. XXXIX. The anemia of infection. Studies on the iron-binding capacity of serum | |
US8716422B2 (en) | Anionic charge-dynamic polymers for release of cationic agents | |
AU2002224475B2 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
CA2182593A1 (en) | Oral liquid compositions containing paroxetine resinate | |
WO2021099973A1 (en) | Injectable compositions of ursodeoxycholic acid | |
WO2020173475A1 (zh) | 一种双药物共递送系统及其制备方法与应用 | |
Hao et al. | Peptide crosslinked micelles: a new strategy for the design and synthesis of peptide vaccines | |
TWI286480B (en) | Pharmaceutical aqueous suspension formulation and method of preparing the same | |
CN101590029B (zh) | 一种丙泊酚组合物 | |
Bhatt-Mehta et al. | Stability of midazolam hydrochloride in extemporaneously prepared flavored gelatin | |
CN109893498A (zh) | 一种多西他赛胶束-凝胶的制备和应用 | |
JPH07316065A (ja) | Fr901469物質製剤 | |
Grieve et al. | Effect of sodium butyrate on synthesis of specific proteins by human breast-carcinoma cells. | |
Wolfson et al. | Solubilization and evaluation of poly-N-vinyl-5-methyl-2-oxazolidinone barbiturate systems | |
TW422827B (en) | The method of enhancing the solubility, stability and releasing rate of shikonin and/or it's derivatives | |
RU2001131715A (ru) | Новая формула N-(4-нитро-2-феноксифенил)метансульфонамида | |
Shah | Formulation and in vitro evaluation of albumin microspheres containing propranolol hydrochloride | |
Simeonova et al. | 3. POLY (BUTYLCYANOACRYLATE) NANOPARTICLES AS POTENTIAL DRUG DELIVERY SYSTEMS | |
CN110799216A (zh) | 用于通过颊内/齿龈途径施用扑热息痛的药物制剂 | |
Mukherjee et al. | One Health Approach and Meta-Analysis for Influenza Prevention | |
Akinyele | Biopharmaceutical and Pharmacokinentic Studies on Various Formulations of Amodiaquine in Artemisinin Combination Therapies | |
TH10612B (th) | สารผสมทางเภสัชกรรมแอโทวาโควน | |
SULFAMETHAZINE | SlILMET*~ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |